BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:22:19 AM | Browse: 433 | Download: 703
 |
Received |
|
2022-02-19 20:11 |
|
Peer-Review Started |
|
2022-02-19 20:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-05-12 08:13 |
|
Revised |
|
2022-05-15 15:24 |
|
Second Decision |
|
2022-07-13 02:49 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-07-18 00:03 |
|
Articles in Press |
|
2022-07-18 00:03 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-18 07:32 |
|
Publish the Manuscript Online |
|
2022-07-22 07:22 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Cautious optimism in anticipation of hepatitis B curative therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alla Turshudzhyan and Micheal Tadros |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alla Turshudzhyan, Consultant, N/A, N/A, Department of Medicine, University of Connecticut, 263 Farmington Avenue
, Farmington, CT 06030-1235, United States. turshudzhyan@uchc.edu |
| Key Words |
Hepatitis B; Hepatitis B virus; Hepatitis B virus entry inhibitor; Bulevirtide; Transcription activator-like effector nucleases; Zinc-finger nucleases; Clustered regularly interspaced short palindromic repeats-associated 9; Nucleocapsid assembly modulators; Hepatitis B virus transcription inhibitors; Hepatitis B surface antigen release inhibitors |
| Core Tip |
Hepatitis B could become a curable disease in the near future. As our understanding of pathophysiology of hepatitis B infection advances, more therapeutic targets are becoming available. Many new therapies have only been investigated in small groups of patients with low viral load and without hepatotoxic injury or in patients with hepatitis D co-infection, which makes it difficult to predict efficacy and side effect profile when applied to the population of interest. Larger clinical trials in hepatitis B patients are needed to further investigate the emerging new therapies, so that more patients can safely benefit from them. |
| Publish Date |
2022-07-22 07:22 |
| Citation |
Turshudzhyan A, Tadros M. Cautious optimism in anticipation of hepatitis B curative therapies. World J Virol 2022; 11(4): 212-215 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i4/212.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i4.212 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
